Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J S de Bono

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Nature|October 1, 2010
Translating cancer research into targeted therapeuticsJ S de Bono, Alan Ashworth
European Journal of Cancer (Oxford, England : 1990)|January 15, 2014
Molecular alterations and emerging targets in castration resistant prostate cancerD Lorente, J S De Bono
Investigational New Drugs|April 9, 2001
The oral fluorinated pyrimidinesJ S de Bono, C J Twelves
Clinical Pharmacology and Therapeutics|July 30, 2017
Application of Liquid Biopsies in Cancer Targeted TherapyS Sumanasuriya, M B Lambros, J S de Bono
British Journal of Cancer|February 19, 2009
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancerJ E Ang, D Olmos, J S de Bono
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
Horizon scanning for novel therapeutics for the treatment of prostate cancerD Bianchini, A Zivi, S Sandhu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitorsA Stewart, P Thavasu, J S de Bono, et al.
Journal of Clinical Pathology|May 23, 2008
Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug developmentG Attard, J E Ang, D Olmos, et al.
Oncogene|May 20, 2014
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospectsR Ferraldeschi, J Welti, J Luo, et al.
BMJ Open|November 28, 2022
What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unitSarah Stapleton, Anne-Sophie Emma Darlington, J S de Bono, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Nature|October 1, 2010
Translating cancer research into targeted therapeuticsJ S de Bono, Alan Ashworth
European Journal of Cancer (Oxford, England : 1990)|January 15, 2014
Molecular alterations and emerging targets in castration resistant prostate cancerD Lorente, J S De Bono
Investigational New Drugs|April 9, 2001
The oral fluorinated pyrimidinesJ S de Bono, C J Twelves
Clinical Pharmacology and Therapeutics|July 30, 2017
Application of Liquid Biopsies in Cancer Targeted TherapyS Sumanasuriya, M B Lambros, J S de Bono
British Journal of Cancer|February 19, 2009
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancerJ E Ang, D Olmos, J S de Bono
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
Horizon scanning for novel therapeutics for the treatment of prostate cancerD Bianchini, A Zivi, S Sandhu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitorsA Stewart, P Thavasu, J S de Bono, et al.
Journal of Clinical Pathology|May 23, 2008
Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug developmentG Attard, J E Ang, D Olmos, et al.
Oncogene|May 20, 2014
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospectsR Ferraldeschi, J Welti, J Luo, et al.
BMJ Open|November 28, 2022
What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unitSarah Stapleton, Anne-Sophie Emma Darlington, J S de Bono, et al.
Pageof 8